To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
153 Newest Publications about the topic cyclophosphamide
rss
Tumefactive demyelination: clinical, imaging and follow‐up observations in thirty‐nine patients
31-12-2012 | M. Nagappa, A. B. Taly, S. Sinha, R. D. Bharath, A. Mahadevan, P. S. Bindu, J. S. Saini, C. Prasad, S. K. Shankar, Acta Neurologica Scandinavica, 2012
Purpose We describe the clinical, neuroimaging and pathological features and therapeutic outcome in a large cohort of 39 patients with tumefactive demyelination. Materials and Methods A retrospective audit of 39 patients with ‘tumefactive demyelination’ was performed. The ...
Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation
19-12-2012 | Moustapha Hassan; Borje S Andersson, Pharmacogenomics, 2012
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant and nonmalignant disorders. Busulfan (Bu) and cyclophosphamide (Cy) are the most commonly used alkylators in high-dose pretransplant conditioning for HSCT; a treatment that is correlated with ...
Influence of counting methodology on erythrocyte ratios in the mouse micronucleus test
07-12-2012 | Matthew J. LeBaron, Melissa R. Schisler, Dorothea K. Torous, Stephen D. Dertinger, B. Bhaskar Gollapudi, Environmental and Molecular Mutagenesis, 2012
Abstract The mammalian erythrocyte micronucleus test is widely used to investigate the potential interaction of a test substance with chromosomes or mitotic apparatus of replicating erythroblasts. In addition to the primary endpoint, micronucleated erythrocyte frequency, the proportion of ...
Monolithic packed 96‐tips set for high‐throughput sample preparation: determination of cyclophosphamide and busulfan in whole blood samples by monolithic packed 96‐tips and LC‐MS
06-12-2012 | Christina Skoglund, Fatma Bassyouni, Mohamed Abdel‐Rehim, Biomedical Chromatography, 2012
ABSTRACT A monolithic methacrylate packed 96‐tips device was used for the extraction of the busulfan and cyclophosphamide in whole blood samples. Using a packed 96‐tips set, a 96‐well plate could be handled in about 2 min. The key aspect of the monolithic phase is that monolithic material ...
Efficient Monitoring of In Vivo Pig-a Gene Mutation and Chromosomal Damage: Summary of 7 Published Studies and Results From 11 New Reference Compounds
01-12-2012 | Stephen D. Dertinger; Souk Phonethepswath; Svetlana L. Avlasevich; Dorothea K. Torous; Jared Mereness; Steven M. Bry ..., Toxicological Sciences, 2012
The ability to effectively monitor gene mutation and micronucleated reticulocyte (MN-RET) frequency in short-term and repeated dosing schedules was investigated using the recently developed flow cytometric Pig-a mutation assay and flow cytometric micronucleus analysis. Eight reference ...
Aggravation of Cyclophosphamide-Induced Acute Neurological Disorders under Conditions of Artificial Acidification of Chyme in Rats
01-11-2012 | T. V. Schäfer, V. L. Rejuniuk, V. N. Malakhovsky, Ju. Ju. Ivnitsky, Bulletin of Experimental Biology and Medicine, 2012
The effect of artificial acidification of the intestinal content on neurological manifestations of acute severe cyclophosphamide intoxication was studied in rats. The animals were gavaged with 20 ml/kg sulfuric (0.05 M), hydrochloric, boric, or lactic acids (0.1 M) 3 h before intraperitoneal ...
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
09-10-2012 | H M Earl; L Hiller; J A Dunn; A-L Vallier; S J Bowden; S D Jordan; F Blows; A Munro; S Bathers; R Grieve; D A Spoone ..., British Journal of Cancer, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials British Journal of Cancer 107, 1257 (9 October 2012). ...
Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas
28-09-2012 | Rinat Bernstein-Molho, Yehuda Kollender, Josephine Issakov, Jacob Bickels, Shlomo Dadia, Gideon Flusser, Isaac Melle ..., Cancer Chemotherapy and Pharmacology, 2012
Objective Chondrosarcomas (CS) represent a heterogeneous group of rare sarcomas, poorly responsive to chemotherapy or radiotherapy. When local therapies in recurrent or metastatic disease are exhausted, chemotherapy plays a marginal role. Different molecular pathways have been shown to be ...
Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine
25-09-2012 | Shiwen Peng, Sofia Lyford-Pike, Belinda Akpeng, Annie Wu, Chien-Fu Hung, Drew Hannaman, John R. Saunders, T.-C. Wu, ..., Cancer Immunology, Immunotherapy, 2012
Although therapeutic HPV vaccines are able to elicit systemic HPV-specific immunity, clinical responses have not always correlated with levels of vaccine-induced CD8+ T cells in human clinical trials. This observed discrepancy may be attributable to an immunosuppressive tumor microenvironment ...
Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
24-09-2012 | Marc C Chamberlain, Expert Review of Neurotherapeutics, 2012
One hundred patients, aged 36–84 years (median 62 years) with recurrent glioblastoma (GBM), were treated previously with surgery, concurrent radiotherapy and temozolomide and postradiotherapy temozolomide followed by single-agent bevacizumab (BEV) at either first (60 patients) or second ...
Netmeeting
